002793.SHE Luoxin Pharmaceuticals Group Stock Co Ltd
- Market cap
- CNY 4.42B
- P/E
- -
- P/B
- 3.75x
- ROE
- 7.1%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002793.SHE undervalued?
Graham numberThe Graham number of Luoxin Pharmaceuticals Group Stock Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Luoxin Pharmaceuticals Group Stock Co Ltd fundamental analysis
No fundamental analysis for Luoxin Pharmaceuticals Group Stock Co Ltd yet.
Luoxin Pharmaceuticals Group Stock Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers healt…
Full company profileLuoxin Pharmaceuticals Group Stock Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Luoxin Pharmaceuticals Group Stock Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.12B | 828M | 6.21B | 7.59B | 6.10B | 6.48B | 3.59B | 2.36B | 2.65B | 2.27B | 2.24B |
| Gross Profit | 3.12B | 252M | 4.28B | 4.79B | 3.25B | 3.25B | 894M | 1.02B | 1.04B | 1.13B | 1.30B |
| Operating Income | 31.6M | 134M | 566M | 725M | 424M | 477M | -1.46B | -586M | -958M | -142M | 185M |
| EBITDA | 542M | 157M | 698M | 927M | 629M | 778M | -1.13B | -337M | -696M | -29.2M | 170M |
| Net Income | 379M | 116M | 512M | 634M | 321M | 406M | -1.22B | -661M | -965M | -289M | 81.9M |
| EPS | 0.62 | 0.34 | 0.48 | 0.57 | 0.22 | 0.28 | -0.86 | -0.61 | -0.91 | -0.27 | 0.08 |
| Balance Sheet | |||||||||||
| Total Assets | 813M | 899M | 1.40B | 7.46B | 7.72B | 9.50B | 8.11B | 5.12B | 4.34B | 3.73B | 3.63B |
| Total Liabilities | 115M | 145M | 492M | 3.50B | 3.37B | 4.76B | 4.80B | 2.54B | 2.88B | 2.49B | 2.42B |
| Shareholders' Equity | 698M | 754M | 910M | 3.68B | 4.04B | 4.38B | 3.17B | 2.47B | 1.38B | 1.16B | 1.15B |
| Cash & Short-term Investments | 140M | 127M | 323M | 1.22B | 1.29B | 2.01B | 1.45B | 695M | 458M | 550M | 794M |
| Total Debt | - | - | 328M | 1.24B | 1.43B | 2.85B | 3.52B | 1.02B | 909M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 72.7M | 102M | 114M | 116M | -32.4M | 121M | -939M | 553M | -158M | 253M | - |
| Capital Expenditure | 71.0M | 161M | 188M | 581M | 361M | 309M | 195M | 242M | 115M | 32.2M | 29.2M |
| Free Cash Flow | 1.74M | -58.8M | -73.8M | -464M | -393M | -188M | -1.13B | 224M | -273M | 221M | 474M |
| Ratios | |||||||||||
| ROE | 54.3% | 15.4% | 56.3% | 17.2% | 7.9% | 9.3% | -38.6% | -26.8% | -69.8% | -24.8% | 7.1% |
| ROA | 46.6% | 12.9% | 36.5% | 8.5% | 4.2% | 4.3% | -15.1% | -12.9% | -22.3% | -7.7% | 2.3% |
| Net Profit Margin | 9.2% | 14.0% | 8.2% | 8.4% | 5.3% | 6.3% | -34.1% | -28.0% | -36.5% | -12.7% | 3.7% |
| Debt to Equity | - | - | 0.36x | 0.34x | 0.35x | 0.65x | 1.11x | 0.41x | 0.66x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Luoxin Pharmaceuticals Group Stock Co Ltd dividends
- Dividend yield
- 1.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 13, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 49.0M | 0.05 | - |
| 2024 | CNY 61.2M | 0.06 | - |
| 2023 | CNY 76.8M | 0.07 | - |
| 2022 | CNY 14.9M | 0.01 | - |
| 2021 | CNY 54.9M | 0.04 | 13.5% |
| 2020 | CNY 72.4M | 0.05 | 22.6% |
| 2019 | CNY 59.5M | 0.05 | 9.4% |
| 2018 | CNY 21.4M | 0.02 | 4.2% |
| 2017 | CNY 60.7M | 0.18 | 52.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.7:1 on Sep 23, 2019.
Who owns Luoxin Pharmaceuticals Group Stock Co Ltd
- Insiders 40.41%
- Institutions 10.23%
- Public & others 49.36%
- Shares outstanding 1.09B
- Free float 643M
Luoxin Pharmaceuticals Group Stock Co Ltd company profile
- Company name
- Luoxin Pharmaceuticals Group Stock Co Ltd
- Ticker
- 002793.SHE
- ISIN
- CNE1000026S7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Machinery
- Employees
- 2,962
- Fiscal year end
- December
- Address
- No. 18, Luoqi Road, Linyi, China, 276017
- Phone
- 86 53 9824 1226
- Website
- luoxin.cn
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers health care services. Luoxin Pharmaceuticals Group Stock Co., Ltd. was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. The company was founded in 1998 and is based in Linyi, China.
Luoxin Pharmaceuticals Group Stock Co Ltd management
3- Mr. Zhenteng LiuGM & Chairman · born 1986
- Mr. Yung-Sheng WuFinance Officer · born 1983
- Hongxing ZhangAccounting Supervisor